{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:58:26Z","timestamp":1790456306485,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":94,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate the feasibility of Simultaneous Amplification and Testing PCA3 (SAT-PCA3, a urine-based prostate cancer-specific biomarker) combined with conventional clinical information in the diagnosis of prostate cancer (PCa).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed 137 patients with complete clinical data. Patients with a biopsy Gleason score\u2009\u2265\u20096 were classified as having PCa. Clinical indicators showing significant differences between PCa and non-PCa groups were identified via univariate analysis. A multivariate model was constructed using pathological diagnosis as the outcome and age, digital rectal exam (DRE) result, prostate-specific antigen (PSA), SAT-PCA3 result, and Prostate Imaging Reporting and Data System (PIRADS) score as predictors. The DeLong test was performed to compare differences in the area under the receiver operating characteristic (ROC) area under the curve (AUC) between the univariate model and the multivariate model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 137 patients were included: 65 were diagnosed with PCa and 72 were non-PCa. Statistical differences existed between the PCa and non-PCa in age, PSA, DRE, PIRADS score, and SAT-PCA3 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). All variables were independently associated with PCa. The coefficient of determination (R\n                      <jats:sup>2<\/jats:sup>\n                      ) values is 0.626 in the multivariate model. The AUCs of the age [0.711(95%CI: 0.625\u20130.796)], DRE [0.626(95%CI: 0.545\u20130.708)], PSA [0.684(95%CI: 0.593\u20130.774)], SAT-PCA3 [0.786(95%CI: 0.706\u20130.866)], PIRADS [0.795(95%CI: 0.722\u20130.866)] were all less than the multivariate model [0.912(95%CI: 0.866\u20130.958)], and the difference was statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A diagnostic model combining conventional clinical information (age, DRE, PSA, PIRADS score) with the SAT-PCA3 significantly improves the diagnostic accuracy for prostate cancer compared to any single parameter alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12672-026-05488-x","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:26:19Z","timestamp":1782260779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multifactorial diagnostic model combining SAT-PCA3 in prostate cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Zeyu","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"3","key":"5488_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"issue":"1","key":"5488_CR2","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1038\/s41598-020-58836-4","volume":"10","author":"J Oto","year":"2020","unstructured":"Oto J, Fern\u00e1ndez-Pardo \u00c1, Royo M, et al. A predictive model for prostate cancer incorporating PSA molecular forms and age. Sci Rep. 2020;10(1):2463.","journal-title":"Sci Rep"},{"issue":"1","key":"5488_CR3","first-page":"20190027","volume":"1","author":"X Filella","year":"2020","unstructured":"Filella X. Towards personalized prostate cancer screening. Adv Lab Med. 2020;1(1):20190027.","journal-title":"Adv Lab Med"},{"issue":"11","key":"5488_CR4","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1007\/s00345-020-03112-3","volume":"38","author":"O Derin","year":"2020","unstructured":"Derin O, Fonseca L, Sanchez-Salas R, Roberts MJ. Infectious complications of prostate biopsy: winning battles but not war. World J Urol. 2020;38(11):2743\u201353.","journal-title":"World J Urol"},{"key":"5488_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.urology.2019.06.011","volume":"133","author":"MD Gross","year":"2019","unstructured":"Gross MD, Alshak MN, Shoag JE, et al. Healthcare Costs of Post-Prostate Biopsy Sepsis. Urology. 2019;133:11\u20135.","journal-title":"Urology"},{"key":"5488_CR6","doi-asserted-by":"crossref","unstructured":"Bardis MD, Houshyar R, Chang PD et al. Applications of Artificial Intelligence to Prostate Multiparametric MRI (mpMRI): Current and Emerging Trends. Cancers 2020;12:5.","DOI":"10.3390\/cancers12051204"},{"key":"5488_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cca.2022.10.018","volume":"537","author":"A Movahedpour","year":"2022","unstructured":"Movahedpour A, Khatami SH, Karami N, et al. Exosomal noncoding RNAs in prostate cancer. Clin Chim Acta. 2022;537:127\u201332.","journal-title":"Clin Chim Acta"},{"key":"5488_CR8","first-page":"149","volume":"15","author":"SM Warli","year":"2023","unstructured":"Warli SM, Warli MH, Prapiska FF. PCA3 and TMPRSS2: ERG Urine Level as Diagnostic Biomarker of Prostate Cancer. Res Rep Urol. 2023;15:149\u201355.","journal-title":"Res Rep Urol"},{"key":"5488_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-1-0716-1354-2_9","volume":"2292","author":"R Gunelli","year":"2021","unstructured":"Gunelli R, Fragal\u00e0 E, Fiori M. PCA3 in Prostate Cancer. Methods Mol biology (Clifton NJ). 2021;2292:105\u201313.","journal-title":"Methods Mol biology (Clifton NJ)"},{"issue":"3","key":"5488_CR10","doi-asserted-by":"publisher","first-page":"L519","DOI":"10.1152\/ajplung.00172.2018","volume":"316","author":"QH Li","year":"2019","unstructured":"Li QH, Zhang Y, Zhao MM, et al. Simultaneous amplification and testing method for Mycobacterium tuberculosis rRNA to differentiate sputum-negative tuberculosis from sarcoidosis. Am J Physiol Lung Cell Mol Physiol. 2019;316(3):L519\u201324.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"5488_CR11","doi-asserted-by":"crossref","unstructured":"Borbiev T, Kohaar I, Petrovics G. Clinical biofluid assays for prostate cancer. Cancers 2023. 16(1):165","DOI":"10.3390\/cancers16010165"},{"issue":"15","key":"5488_CR12","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/pros.24608","volume":"83","author":"J Li","year":"2023","unstructured":"Li J, Wang K, Li S, et al. Clinical study of multifactorial diagnosis in prostate biopsy. Prostate. 2023;83(15):1494\u2013503.","journal-title":"Prostate"},{"issue":"3","key":"5488_CR13","doi-asserted-by":"publisher","first-page":"e103117","DOI":"10.1016\/j.urolonc.2021.09.015","volume":"40","author":"F Barletta","year":"2022","unstructured":"Barletta F, Stabile A, Mazzone E, et al. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series. Urol Oncol. 2022;40(3):e103117\u201324.","journal-title":"Urol Oncol"},{"issue":"3","key":"5488_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.prnil.2024.06.001","volume":"12","author":"B \u015eahin","year":"2024","unstructured":"\u015eahin B, \u00c7elik S, S\u00f6zen S, et al. A new parameter to increase the predictive value of multiparametric prostate magnetic resonance imaging for clinically significant prostate cancer in targeted biopsies: lesion density. Prostate Int. 2024;12(3):145\u201350.","journal-title":"Prostate Int"},{"issue":"2","key":"5488_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/RCT.0000000000001679","volume":"49","author":"H Nakai","year":"2025","unstructured":"Nakai H, Takahashi H, LeGout JD, et al. Prostate Cancer Risk Prediction Model Using Clinical and Magnetic Resonance Imaging-Related Findings: Impact of Combining Lesions\u2019 Locations and Apparent Diffusion Coefficient Values. J Comput Assist Tomogr. 2025;49(2):247\u201357.","journal-title":"J Comput Assist Tomogr"},{"issue":"1","key":"5488_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12957-024-03643-8","volume":"22","author":"X Shu","year":"2024","unstructured":"Shu X, Wang J, Cai W, et al. Clinical assessment of urinary prostate cancer antigen 3 in Chinese population: a large-scale, prospective and multicenter study. World J Surg Oncol. 2024;22(1):355.","journal-title":"World J Surg Oncol"},{"issue":"12","key":"5488_CR17","first-page":"e75390","volume":"16","author":"A Debo-Aina","year":"2024","unstructured":"Debo-Aina A, Martindale A, Amjad J, Smekal M, Nkwam N. The Value of Digital Rectal Examination (DRE) in Prostate Cancer Diagnostics. Cureus. 2024;16(12):e75390.","journal-title":"Cureus"},{"issue":"4","key":"5488_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/14796694.2024.2445499","volume":"21","author":"F Liu","year":"2025","unstructured":"Liu F, Wang J, Song Y, et al. A nomogram with coagulation markers for prostate cancer prediction in patients with PSA levels of 4\u201320 ng\/mL. Future Oncol (London England). 2025;21(4):463\u201371.","journal-title":"Future Oncol (London England)"},{"issue":"6","key":"5488_CR19","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1016\/j.acra.2024.12.006","volume":"32","author":"NB Lomer","year":"2025","unstructured":"Lomer NB, Ashoobi MA, Ahmadzadeh AM, Sotoudeh H, Tabari A, Torigian DA. MRI-based Radiomics for Predicting Prostate Cancer Grade Groups: A Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies. Acad Radiol. 2025;32(6):3429\u201352.","journal-title":"Acad Radiol"},{"issue":"3","key":"5488_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41416-024-02934-x","volume":"132","author":"L Luo","year":"2025","unstructured":"Luo L, Wang R, Bai L, et al. The accuracy of fluorine 18-labelled prostate-specific membrane antigen PET\/CT and MRI for diagnosis of prostate cancer in PSA grey zone. Br J Cancer. 2025;132(3):253\u20138.","journal-title":"Br J Cancer"},{"issue":"9","key":"5488_CR21","doi-asserted-by":"publisher","first-page":"e527517","DOI":"10.1016\/j.urolonc.2025.05.007","volume":"43","author":"Z Luo","year":"2025","unstructured":"Luo Z, Li J, Wang K, et al. Study of AI algorithms on mpMRI and PHI for the diagnosis of clinically significant prostate cancer. Urol Oncol. 2025;43(9):e527517\u201324.","journal-title":"Urol Oncol"},{"issue":"6","key":"5488_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.eururo.2023.09.002","volume":"84","author":"E Beatrici","year":"2023","unstructured":"Beatrici E, Labban M, Stone BV, et al. Uncovering the Changing Treatment Landscape for Low-risk Prostate Cancer in the USA from 2010 to 2020: Insights from the National Cancer Data Base. Eur Urol. 2023;84(6):527\u201330.","journal-title":"Eur Urol"},{"issue":"12","key":"5488_CR23","doi-asserted-by":"publisher","first-page":"e483411","DOI":"10.1016\/j.urolonc.2023.09.012","volume":"41","author":"E Beatrici","year":"2023","unstructured":"Beatrici E, Filipas DK, Stone BV, et al. Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade. Urol Oncol. 2023;41(12):e483411\u20139.","journal-title":"Urol Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05488-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05488-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05488-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:02:23Z","timestamp":1790452943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05488-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5488"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05488-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study involving human data in accordance with the ethical principles of the Declaration of Helsinki and received approval from the institutional review board of the Affiliated Hospital of Jiaxing University (IRB number: 2024-LY-607). Written informed consent was obtained from all human participants involved in the research.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1381"}}